Sickle Cell Disease in 2024: Breakthroughs Changing Everything

Sickle cell disease is in the middle of a therapeutic revolution. In December 2023, the FDA approved two gene therapies — Casgevy (exagamglogene autotemcel) and Lyfgenia (lovotibeglogene autotemcel) — marking the first time CRISPR-based gene editing was approved for any human disease. For roughly 100,000 Americans living with SCD, and millions more worldwide, these approvals represent the most significant shift in treatment since hydroxyurea arrived in 1998. This article covers the latest news and developments in sickle cell disease management and research, from gene therapy to novel medications to updated clinical guidelines.

Appreciating how far these advances reach becomes easier alongside the history of sickle cell disease management, which traces the long path from first identification to today’s targeted therapies.

If you or someone you love has sickle cell disease, there’s genuine reason for optimism right now. Beyond gene therapy, new drugs targeting different parts of SCD pathophysiology have entered the market, clinical trials are producing encouraging data, and global efforts to expand access to curative treatments are gaining momentum.

Quick Refresher: What Is Sickle Cell Disease?

Sickle cell disease (SCD) is an inherited blood disorder caused by a point mutation in the HBB gene. This mutation swaps glutamic acid for valine at position 6 of the beta-globin chain, producing abnormal hemoglobin S (HbS). Under low-oxygen conditions, HbS polymerizes, deforming red blood cells into rigid, crescent-shaped “sickles” that clog small blood vessels and break apart prematurely.

SCD follows an autosomal recessive inheritance pattern. You need two copies of the mutated gene (HbSS, or compound heterozygous forms like HbSC or HbS/β-thalassemia) to have the disease. Carriers with one copy (sickle cell trait, HbAS) are generally asymptomatic but can pass the gene to children.

The disease disproportionately affects people of African, Mediterranean, Middle Eastern, and South Asian descent — populations where malaria is or was endemic, since carrying one sickle gene confers some protection against Plasmodium falciparum.

The Clinical Reality of SCD

SCD isn’t one problem — it’s a cascade of them. Vaso-occlusion, chronic hemolysis, and progressive organ damage define the disease course. Here’s what patients actually deal with:

• Vaso-occlusive crises (VOCs): Excruciating pain episodes lasting days to weeks, often requiring hospitalization and IV opioids
• Chronic anemia: Baseline hemoglobin typically runs 6–9 g/dL (normal: 12–16 g/dL), causing persistent fatigue
• Acute chest syndrome: A leading cause of death in SCD, resembling pneumonia with fever, chest pain, and pulmonary infiltrates
• Stroke: Affects up to 11% of children with SCD by age 20 without screening and prophylactic transfusions
• Organ damage: Progressive injury to the spleen, kidneys, liver, lungs, and bones — often beginning in childhood
• Shortened lifespan: Median survival in the U.S. is approximately 43–54 years, though this is improving

Latest Breakthroughs in SCD Treatment (2023–2024)

Gene Therapy: The Curative Frontier

The two FDA-approved gene therapies work differently but aim for the same goal — eliminating or drastically reducing sickling:

These are functionally curative for many patients, but the barriers are real: cost, the need for intensive chemotherapy conditioning, limited treatment centers, and long-term safety data that’s still accumulating. Currently, most candidates are patients aged 12 and older with recurrent VOCs.

Newer FDA-Approved Medications

For patients who aren’t candidates for gene therapy — which is most people with SCD right now — several newer drugs have changed day-to-day management:

• Voxelotor (Oxbryta): Inhibits HbS polymerization by increasing hemoglobin’s oxygen affinity. Raised hemoglobin by ~1 g/dL in trials. Note: Pfizer voluntarily withdrew Oxbryta in September 2024 after post-marketing data raised concerns about VOC outcomes, though hemoglobin benefits were confirmed.
• Crizanlizumab (Adakveo): Anti-P-selectin antibody that reduces cell adhesion. The initial SUSTAIN trial showed a 45% reduction in annual VOCs, but the larger STAND trial failed to meet its primary endpoint, raising questions about real-world efficacy.
• L-glutamine (Endari): Approved in 2017, reduces oxidative stress in sickled cells. Reduced acute complications by 25% in the phase 3 trial.
• Hydroxyurea: Still the backbone of SCD management after 25+ years. Boosts fetal hemoglobin (HbF), reduces VOCs by 44%, and decreases mortality. Tragically underused — only about 25% of eligible patients in the U.S. are on it.

What’s in the Pipeline

Several promising therapies are in clinical trials as of 2024:

• Fitusiran: An antithrombin-targeting siRNA being studied for SCD-related coagulation issues
• Inclacumab: Another anti-P-selectin agent in phase 3 trials
• In vivo gene editing: Companies like Beam Therapeutics are developing base-editing approaches that wouldn’t require harvesting stem cells or myeloablative chemo — potentially a game-changer for access
• Allogenic gene-edited cell therapies: Off-the-shelf products that could bypass the individualized manufacturing process

Diagnosis: How SCD Is Detected Today

Newborn screening catches most cases in developed countries. In the U.S., all 50 states screen for SCD at birth using high-performance liquid chromatography (HPLC), isoelectric focusing, or capillary electrophoresis. Confirmatory testing with hemoglobin electrophoresis or DNA analysis follows a positive screen.

For older patients or those from regions without newborn screening, a solubility test (Sickledex) can suggest the presence of HbS, but it can’t distinguish trait from disease and misses other hemoglobin variants. Full hemoglobin analysis is always needed.

Transcranial Doppler (TCD) ultrasonography is standard annual screening for stroke risk in children aged 2–16 with HbSS. A time-averaged mean velocity ≥200 cm/s in the middle cerebral or internal carotid artery triggers chronic transfusion therapy, which reduces stroke risk by ~90%.

When to See a Doctor

If you have SCD, seek emergency care for:

• Fever ≥101.3°F (38.5°C) — this is a medical emergency in SCD due to functional asplenia and infection risk
• Chest pain, difficulty breathing, or rapid breathing (possible acute chest syndrome)
• Sudden weakness, severe headache, or slurred speech (possible stroke)
• Sudden vision changes
• Painful erection lasting >4 hours (priapism)
• Pain not controlled by home medications
• Sudden enlargement of the spleen (splenic sequestration — especially in young children)

Even outside crises, patients should see their hematologist every 3–6 months for monitoring of organ function, hemoglobin levels, and medication management.

Frequently Asked Questions

Can sickle cell disease be cured now?

Yes — for some patients. Bone marrow transplant from a matched sibling donor has been curative for decades, with success rates above 90% in children. The newly approved gene therapies (Casgevy and Lyfgenia) offer a curative option without needing a matched donor. However, access remains extremely limited due to cost, treatment complexity, and the requirement for intensive chemotherapy before the procedure.

How long do people with sickle cell disease live?

Life expectancy has improved significantly. In the 1970s, median survival was about 14 years. Today, with hydroxyurea, transfusion programs, and better supportive care, median survival in the U.S. is roughly 43–54 years, depending on genotype and access to care. HbSC disease generally has a milder course and longer life expectancy than HbSS. Gene therapy could push these numbers much higher for treated patients.

Is sickle cell trait dangerous?

Sickle cell trait (HbAS) is generally benign. However, it’s not completely risk-free. Rare but documented complications include exercise-related sudden death (particularly in military recruits and athletes at altitude), hematuria from renal papillary necrosis, and splenic infarction at high altitude. The absolute risk of these events is very low, and routine restrictions on activity aren’t recommended — but staying hydrated and acclimatizing to altitude is sensible advice.

Why is hydroxyurea underused if it works so well?

This is one of the most frustrating problems in SCD care. Despite strong evidence that hydroxyurea reduces pain crises, hospitalizations, acute chest syndrome, and mortality, only about 25% of eligible patients in the U.S. take it. Reasons include provider hesitancy, patient concerns about side effects (particularly fertility — though evidence suggests it’s safe), inconsistent prescribing in non-specialist settings, and systemic healthcare inequities that disproportionately affect the predominantly Black patient population.

What’s the most exciting research development right now?

In vivo gene editing — meaning editing genes directly inside the patient’s body without removing and transplanting stem cells. If successful, this could eliminate the need for myeloablative chemotherapy and make gene-based cures accessible to patients in sub-Saharan Africa and other resource-limited settings where the majority of SCD patients live. Early-phase trials are underway, and results are expected within the next 2–3 years.

Key Takeaways

• SCD treatment has entered a transformative era with two FDA-approved gene therapies offering functional cures for eligible patients
• Hydroxyurea remains the most impactful and accessible treatment — ask about it if you’re not already on it
• The post-marketing withdrawal of Oxbryta and mixed results for crizanlizumab remind us that newer doesn’t always mean better
• Newborn screening, TCD monitoring, and penicillin prophylaxis in children remain cornerstones of reducing early mortality
• The next frontier — in vivo gene editing — could democratize curative therapy for the millions of patients in low-resource settings who need it most